Immunohistochemical detection of prothymosin alpha in pituitary adenomas - A new marker of tumor recurrence?

Folia Histochemica et Cytobiologica

Volumn 47, Issue 4, 2009, Pages 559-562

  Pawlikowski, Marek ^a   Winczyk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Ki 67; Pituitary adenomas; Prognostic factors; Prothymosin alpha

Indexed keywords

KI 67 ANTIGEN; PROTHYMOSIN ALPHA;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; GONADOTROPH ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; PREDICTION; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

EID: 77954392406     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0096-2     Document Type: Article

References (18)

1. Pineiro A, Cordero OJ, Noguiera M. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides. 2000;21:1433-1446.
2. Letsas KP, Frangou-Lazaridis M. Surfing on prothymosin alpha proliferation and anti-apoptotic properties. Neoplasma. 2006;53:92-96.
3. Sburlati AR, Manrow RE, Berger SL. Prothymosin alpha antisense oligomers inhibit myeloma cell division. Proc Natl Acad Sci USA. 1991;88:253-257.
4. Leys CM, Nomura S, LaFleur BJ et al. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2007;141:41-50.
5. Suzuki S, Takahashi S, Takeshita K et al. Expression of prothymosin alpha is correlated with development and pro- gression in human prostatic cancers. Prostate. 2006;66: 463-469.
6. Klimentzou P, Drougou A, Fehrenbacher B et al. Immunocy- tological and preliminary immunohistochemical studies of peothymnosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody. J Histochem Cytochem. 2008;56:1023-1031.
7. Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M. Fine needle aspiration biopsy RT-PCR expres- sion analysis of prothymosin alpha and parathymosin in thy roid: novel proliferation markers? Neoplasma. 2007;54:57-62.
8. Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int. 2005;55:694-702.
9. [9]Pawlikowski M. Immunostaining of thymosin peptides in human pituitary adenomas. Int J Thymol. 1999;7:607-611.
10. Pawlikowski M. Immunohistochemical markers of pituitary tumor aggressiveness (in polish). Endokr Pol-Polish J Endocrinol. 2002;53(suppl 1):238-242.
11. Słwiñska-Klencka D, Klencki M, Dedecjus M, Lewiñski A, Pawlikowski M. Silver-staining nucleolar organizer region quantification in pituitary adenomas. Endocrine Pathol. 2000;11:173-178.
12. Klencki M, Słwinska-Klencka D, Lewinski A, Pawlikowski M. Correlation between PCNA expression and AgNOR dots in pituitary adenomas. Endocr Pathol. 2001;12:163-169
13. Hsu DW, Hakim F, Biller BM et al. Significance of prolifer- ating cell nuclear antigen index in predicting pituitary tumor recurrence. J Neurosurg. 1993;78:753-761.
14. Pawlikowski M, Gruszka A, Kurnatowska I, Winczyk K, Kunert-Radek J, Radek A Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol. 2006;44:37-41.
15. Paek KI, Kim SH, Song SH et al. Clinical significance of Ki- 67 labeling index in pituitary macroadenoma. J Korean Med Sci. 2005;20:489-494.
16. Losa N, Franzin A, Mangili F et al. Proliferation index of non- functioning pituitary adenomas: correlation with clinical characteristics and long-term follow-up results. Neuro-surgery. 2000;47:1313-1318.
17. Turner HE, Wass JA. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary. 1999;1:147-151.
18. Grant DS, Kinsella JL, Kibbey MC et al. A matrigel induced gene involved in endothelial cell proliferation and angiogenesis. J Cell Sci. 1995; 108: 3683-3694.